{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:08:02Z","timestamp":1787162882699,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory arthritis in children with Down syndrome (DS) was first described in 1984 and is now termed Down syndrome-associated arthritis (DA). Studies have shown that DA is under-recognized with a 19-month average delay in diagnosis. Additionally, most patients present with polyarticular, rheumatoid factor (RF) and anti-nuclear antibody (ANA) negative disease. Current therapies for juvenile idiopathic arthritis (JIA) have been used, but appear to be poorly tolerated, more toxic and less effective in patients with DA. There is currently no standardized approach to the assessment or management of DA. The objective of this study was to describe provider perspectives toward diagnostic and treatment approach of DA, to provide baseline information upon which to design future studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An electronic survey, organized into sections regarding individual practices of assessment and treatment approach of DA, was sent to the Pediatric Rheumatology electronic list-serv. Survey responses were voluntary and results were analyzed by descriptive statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 90 survey responses received, 89 were included in the analysis (one was a duplicate response). The respondents were mostly pediatric rheumatologist (94%), with greater than 10\u2009years of experience (55%). The majority (64%) currently see 1\u20133 patients with DA. Most view DA as the same disease as JIA (73%), and the majority (63%) use a combination of history, exam and imaging to diagnose DA. The most ordered diagnostic tests are CBC (97%) and ESR (96%). The most used treatments include NSAIDs (94%) and methotrexate (91%) followed by anti-TNF agents (90%). Methotrexate is most administered by subcutaneous route (84%) at a dose of 15\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (56%). Oral corticosteroids were only used in 19% of the patients with DA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study to evaluate provider perspectives towards the diagnostic and treatment approach of DA. Most pediatric rheumatologists feel that DA and JIA are synonymous, and similar approaches to diagnosis are employed, utilizing history, physical exam, laboratory tests, and imaging modalities. DA is treated similarly to JIA with initiation of NSAIDs, disease-modifying anti-rheumatic drugs and biologic therapy. More research is needed to determine optimal screening and therapeutic approach specific to DA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-020-00445-6","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T07:04:10Z","timestamp":1594623850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Assessment and treatment of Down syndrome-associated arthritis: a survey of pediatric rheumatologists"],"prefix":"10.1186","volume":"18","author":[{"given":"Anna","family":"Nicek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Talib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0986-4991","authenticated-orcid":false,"given":"Jordan T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"issue":"4","key":"445_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/ajmg.a.37001","volume":"167A","author":"G de Graaf","year":"2015","unstructured":"de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A. 2015;167A(4):756\u201367.","journal-title":"Am J Med Genet A."},{"key":"445_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12929-015-0138-y","volume":"22","author":"A Asim","year":"2015","unstructured":"Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S. Down syndrome: an insight of the disease. J Biomed Sci. 2015;22:41.","journal-title":"J Biomed Sci."},{"issue":"3","key":"445_CR3","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/ajmg.a.33295","volume":"152A","author":"M Shin","year":"2010","unstructured":"Shin M, Siffel C, Correa A. Survival of children with mosaic Down syndrome. Am J Med Genet A. 2010;152A(3):800\u20131.","journal-title":"Am J Med Genet A."},{"issue":"2","key":"445_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/pai.13133","volume":"31","author":"RHJ Verstegen","year":"2020","unstructured":"Verstegen RHJ, Chang KJJ, MAA K. Clinical implications of immune-mediated diseases in children with Down syndrome. Pediatr Allergy Immunol. 2020;31(2):117\u201323.","journal-title":"Pediatr Allergy Immunol."},{"issue":"8","key":"445_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.1780270813","volume":"27","author":"CL Yancey","year":"1984","unstructured":"Yancey CL, Zmijewski C, Athreya BH, Doughty RA. Arthropathy of Down's syndrome. Arthritis Rheum. 1984;27(8):929\u201334.","journal-title":"Arthritis Rheum."},{"issue":"2","key":"445_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jpeds.2008.07.056","volume":"154","author":"H Juj","year":"2009","unstructured":"Juj H, Emery H. The arthropathy of Down syndrome: an underdiagnosed and under-recognized condition. J Pediatr. 2009;154(2):234\u20138.","journal-title":"J Pediatr."},{"issue":"1","key":"445_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40272-018-0322-0","volume":"21","author":"JT Jones","year":"2019","unstructured":"Jones JT, Talib N, Lovell D, Becker ML. Clinical features and treatment of Down syndrome Arthropathy: experience from two US tertiary hospitals. Paediatr Drugs. 2019;21(1):33\u20139.","journal-title":"Paediatr Drugs."},{"issue":"1","key":"445_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000890","volume":"5","author":"CM Foley","year":"2019","unstructured":"Foley CM, Deely DA, MacDermott EJ, Killeen OG. Arthropathy of Down syndrome: an under-diagnosed inflammatory joint disease that warrants a name change. RMD Open. 2019;5(1):e000890.","journal-title":"RMD Open."},{"issue":"6","key":"445_CR9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1542\/peds.86.6.931","volume":"86","author":"JC Olson","year":"1990","unstructured":"Olson JC, Bender JC, Levinson JE, Oestreich A, Lovell DJ. Arthropathy of Down syndrome. Pediatrics. 1990;86(6):931\u20136.","journal-title":"Pediatrics."},{"issue":"5","key":"445_CR10","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/archdischild-2018-315751","volume":"104","author":"C Foley","year":"2019","unstructured":"Foley C, Killeen OG. Musculoskeletal anomalies in children with Down syndrome: an observational study. Arch Dis Child. 2019;104(5):482\u20137.","journal-title":"Arch Dis Child."},{"issue":"6","key":"445_CR11","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/art.40884","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Rheumatol. 2019;71(6):846\u201363.","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"445_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/BF00444952","volume":"146","author":"M Peeters","year":"1987","unstructured":"Peeters M, Poon A. Down syndrome and leukemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr. 1987;146(4):416\u201322.","journal-title":"Eur J Pediatr."},{"issue":"4","key":"445_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jpeds.2013.11.032","volume":"164","author":"NJ Roizen","year":"2014","unstructured":"Roizen NJ, Magyar CI, Kuschner ES, Sulkes SB, Druschel C, van Wijngaarden E, et al. A community cross-sectional survey of medical problems in 440 children with Down syndrome in New York state. J Pediatr. 2014;164(4):871\u20135.","journal-title":"J Pediatr."},{"issue":"10","key":"445_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/rheumatology\/41.10.1191","volume":"41","author":"B Padmakumar","year":"2002","unstructured":"Padmakumar B, Evans Jones LG, Sills JA. Is arthritis more common in children with Down syndrome? Rheumatology. 2002;41(10):1191\u20133.","journal-title":"Rheumatology."},{"issue":"1","key":"445_CR15","doi-asserted-by":"publisher","first-page":"14818","DOI":"10.1038\/s41598-017-13858-3","volume":"7","author":"KD Sullivan","year":"2017","unstructured":"Sullivan KD, Evans D, Pandey A, Hraha TH, Smith KP, Markham N, et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci Rep. 2017;7(1):14818.","journal-title":"Sci Rep."},{"issue":"4","key":"445_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41150","volume":"72","author":"C Foley","year":"2020","unstructured":"Foley C, Floudas A, Canavan M, Biniecka M, EJ MD, Veale DJ, et al. Increased T Cell Plasticity With Dysregulation of Follicular Helper T, Peripheral Helper T, and Treg Cell Responses in Children With Juvenile Idiopathic Arthritis and Down Syndrome-Associated Arthritis. Arthritis Rheumatol. 2020;72(4):677\u201386.","journal-title":"Arthritis Rheumatol."},{"key":"445_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10875-020-00755-0","volume":"40","author":"G Ottaviano","year":"2020","unstructured":"Ottaviano G, Gerosa J, Santini M, De Leo P, Vecchione A, Jofra T, et al. A prevalent CXCR3(+) phenotype of circulating follicular helper T cells indicates Humoral Dysregulation in children with Down syndrome. J Clin Immunol. 2020;40:447\u201355.","journal-title":"J Clin Immunol."},{"issue":"2","key":"445_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1542\/peds.2011-1605","volume":"128","author":"MJ Bull","year":"2011","unstructured":"Bull MJ. Committee on G. health supervision for children with Down syndrome. Pediatrics. 2011;128(2):393\u2013406.","journal-title":"Pediatrics."},{"issue":"2","key":"445_CR19","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol."},{"issue":"11","key":"445_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrrheum.2009.209","volume":"5","author":"C Macaubas","year":"2009","unstructured":"Macaubas C, Nguyen K, Milojevic D, Park JL, Mellins ED. Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol. 2009;5(11):616\u201326.","journal-title":"Nat Rev Rheumatol."},{"issue":"1073","key":"445_CR21","doi-asserted-by":"publisher","first-page":"20160920","DOI":"10.1259\/bjr.20160920","volume":"90","author":"HAS Basra","year":"2017","unstructured":"Basra HAS, Humphries PD. Juvenile idiopathic arthritis: what is the utility of ultrasound? Br J Radiol. 2017;90(1073):20160920.","journal-title":"Br J Radiol."},{"issue":"4","key":"445_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/pan.12841","volume":"26","author":"AF Lewanda","year":"2016","unstructured":"Lewanda AF, Matisoff A, Revenis M, Harahsheh A, Futterman C, Nino G, et al. Preoperative evaluation and comprehensive risk assessment for children with Down syndrome. Paediatr Anaesth. 2016;26(4):356\u201362.","journal-title":"Paediatr Anaesth."},{"issue":"1","key":"445_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","volume":"16","author":"G Ferrara","year":"2018","unstructured":"Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46.","journal-title":"Pediatr Rheumatol Online J."},{"key":"445_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ridd.2016.06.018","volume":"57","author":"F Bertapelli","year":"2016","unstructured":"Bertapelli F, Pitetti K, Agiovlasitis S, Guerra-Junior G. Overweight and obesity in children and adolescents with Down syndrome-prevalence, determinants, consequences, and interventions: a literature review. Res Dev Disabil. 2016;57:181\u201392.","journal-title":"Res Dev Disabil."},{"issue":"7","key":"445_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3324\/haematol.2009.019778","volume":"95","author":"TD Buitenkamp","year":"2010","unstructured":"Buitenkamp TD, Mathot RA, de Haas V, Pieters R, Zwaan CM. Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica. 2010;95(7):1106\u201313.","journal-title":"Haematologica."},{"issue":"1","key":"445_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/pbc.20092","volume":"44","author":"JW Taub","year":"2005","unstructured":"Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44(1):33\u20139.","journal-title":"Pediatr Blood Cancer."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00445-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-020-00445-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00445-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T10:14:52Z","timestamp":1667384092000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-020-00445-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1186\/s12969-020-00445-6","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IRB approved.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}